Founded in 2021 by Dr. Zhiqian Zhang - a Generation Z, Tidetron Bioworks Technology Co., Ltd. is one of the world’s first synthetic bio-manufacturing platforms to realize mass production of various substances. In just 10 months, we have been financed over $100 million and recognized as a new star of synthetic biology worldwide.

We adhere to the principle of "It’s growing" and is committed to synthetic biotechnology innovation to meet people's new requirements on medicine, food, cosmetics, safety. Now we have established a chain from R&D to production and built our unique Tidetron Altra platform-based strain library and component library. We have made absolute breakthroughs in mass production and universality. Our factory could provide customized production, with an annual production capacity exceeding 10,000 tons.

At present, there are more than 30 substances on sale, including peptides, erythritol, and bulk commodities. We also provide integrated enterprise-universities-researches solutions in skin care, food and beverage, household cleaning, biomedicine, etc.

We built a "quick response" system with its exclusive technology, which has broken the bottleneck in transforming and applying. Efficient mass production technology makes the traditional mode of production enter "environmental protection mutation", and the industrial chain realizes a green upgrade. In the trend of green life, Tidetron, which influences Environmental, Social and Governance (ESG) and end products in the industry, is turning synthetic biology into the fundamental force that changes traditional production and making more people achieve the carbon peaking and carbon neutrality goals in daily life.


November 2016
November 2016

The 1st Trophy

Zhiqian Zhang, the founder of Tidetron, began to devote himself to the research after being exposed to synthetic biology during his Ph.D. at Sun Yat-sen University. As a representative of Chinese students, he participated in iGEM and won three awards: the Gold Medal in the Finals, the Best Therapeutics Project and the Best New Composite Part.

June 2017
June 2017

The 1st Laboratory

Zhiqian Zhang realized that synthetic biology has great potential, while mass production and commercial construction are common problems of the industry. He also realized that the most important thing is how to apply synthetic biology to real industrial production. Thus, he began to set up R&D laboratories with the goal of mass production.

October 2020
October 2020

The 1st Victory against Difficulty

After four years of research, the Tidetron Altra platform-based strain library with the value of universal application was successfully built in the laboratory, a milestone progress involved in mass production and universality.

April 2021
April 2021

The 1st factory

Tidetron’s intelligent factory was put into use, and the customized intelligent fermentation system provided ultra-mild production mode with low energy consumption, less pollution and low carbon emission.

November 2021
November 2021

The 1st Transcendence

The number of mass-produced substances reaches more than 30, covering various fields such as specialized skin care, food and beverage, household cleaning, biomedicine, etc. We are the first to realize multi-substance mass production in the industry.

December 2021
December 2021

The 1st Cooperation

We take the strategy of scientific research driving production and create a enterprises-universities-researches model. Tidetron has successively carried out joint research and practical cooperation with scientific research units such as Sun Yat-sen University, Jiangnan University, and the Key Laboratory of Materials Chemical Engineering, etc.

January 2022
January 2022

The 1st over $100 million financing

Four rounds of financing were completed within 10 months. The investment institutions included Unity Ventures, ZhenFund, Legend Capital, IDG Capital, etc., accumulating financing that exceeds $100 million.

April 2022
April 2022

The 1st hardware upgrade

The laboratory was expanded to 2,000 square meters. The hardware equipment was upgraded again, and the members of the scientific research family increased exponentially; We further improved the research and production space in a lively atmosphere, and keep chasing technological innovation.


Zhiqian Zhang

founder, CEO

Zhiqian Zhang currently pursues a Ph.D. degree of clinical medicine in School of Medicine, SYSU.
Zhiqian has visited Yale School of Medicine and engaged in research at South China Stem Cell Research Center, Zhongshan Ophthalmology Center and Cardiovascular Center of Yale University.
In 2016, he won the Gold Medal, the Best Therapeutics Project and the Best New Composite Part of iGEM.
He has been listed on the 2021 Forbes China "30 under 30". Zhiqian now takes in charge of overall management and R&D.

Xianzhi Wang


Xianzhi Wang once worked for IDG Capital, and engaged in investment in the consumption and technology industries for 5 years. He participated in the investment over ¥1 billion. He was responsible for the post-investment management of 8 invested enterprises.
:: Currently responsible for strategy and development, investment and finance, and government relations

750 x 1000-2

Kevin Zhang


Kevin Zhang has over 20+ years of B2B chemical business leadership experience in Asia Pacific and Greater China in leading MNCs among DuPont, INVISTA, CRISTAL, and Ferro.
The first Chinese executive once drove the business in two global top tier TiO2 companies respectively with strong position in the global business steering team.
Kevin also has the soundtrack record for successful integration of business team for high performance after acquisition of Chinese local and MNC mills, Kevin holds the MBA degree from HKUST.

Yirui Wu

Chief Scientist

Dr. Yirui Wu received his Ph.D. degree in microbiology from the City University of HK. He has served as a research fellow of the National University of Singapore, professor at the Shantou University and visiting professor of the University of Technology Sydney.
He has made a series of innovative achievements in microbial metabolic engineering and biotransformation of high value-added bio-based products.
He has published more than 30 papers in international top journals , and presided over and participated in more than 10 talent projects.



Leave your valuable information in order to provide you with better services